Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 1/20 | 0.63 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.49 |
| ▸ | GRIN1 | Q05586 | 4/20 | 0.34 |
| ▸ | GRIN2B | Q13224 | 4/20 | 0.34 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.33 |
| ▸ | MTOR | P42345 | 1/20 | 0.33 |
| ▸ | GRM5 | P41594 | 5/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6551931 | 0.81 | CHRNA7 (0.47) | PIK3CDCHRNA7LMNA | |
| SCHEMBL23505992 | 0.79 | PIK3CD (0.46) | PIK3CDCHRNA7GRM5 | |
| SCHEMBL12058789 | 0.79 | PIK3CD (0.69) | PIK3CDCHRNA7GRIN1GRIN2B | |
| SCHEMBL8282177 | 0.78 | PIK3CD (1.00) | PIK3CDCHRNA7GRIN1GRIN2B | |
| SCHEMBL9509104 | 0.78 | PIK3CD (0.58) | PIK3CDCHRNA7GRIN1GRIN2BGRM5 | |
| SCHEMBL15354726 | 0.77 | PIK3CD (0.72) | PIK3CDCHRNA7GRIN1GRIN2B | |
| SCHEMBL15354755 | 0.77 | PIK3CD (0.72) | PIK3CDCHRNA7GRIN1GRIN2B | |
| SCHEMBL24251064 | 0.76 | PIK3CD (0.56) | PIK3CDCHRNA7GRIN1GRIN2B | |
| SCHEMBL23518166 | 0.76 | PIK3CD (0.65) | PIK3CDCHRNA7GRIN1GRIN2B | |
| SCHEMBL23518055 | 0.76 | PIK3CD (0.65) | PIK3CDCHRNA7GRIN1GRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0885941-B1 | Ink jet inks containing oxazolidinones | XEROX CORP (US) | 2004-02-18 | — | — | EP | claimed |
| US-5882389-A | WATER, COLOR AND OXAZOLIDINONE | XEROX CORPORATION (US) | 1999-03-16 | — | — | US | claimed |
| EP-3209664-B1 | BICYCLIC HETEROARYL AMINE COMPOUNDS AS PI3K INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2020-06-03 | — | — | EP | disclosed |
| US-20170355707-A1 | BICYCLIC HETEROARYL AMINE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2017-12-14 | — | — | US | disclosed |
| US-9809541-B2 | LSD1 inhibitors | Mirati Therapeutics, Inc. (US) | 2017-11-07 | — | — | US | disclosed |
| WO-2017116558-A1 | LSD1 INHIBITORS | Mirati Therapeutics, Inc. (US) | 2017-07-06 | — | — | WO | disclosed |
| US-20170183308-A1 | LSD1 Inhibitors | Mirati Therapeutics, Inc. (US) | 2017-06-29 | — | — | US | disclosed |
| WO-2017079476-A1 | LSD1 INHIBITORS | Mirati Therapeutics, Inc. (US) | 2017-05-11 | — | — | WO | disclosed |
| US-8791111-B2 | Piperidine and piperazine derivatives | MERCK PATENT GMBH (DE) | 2014-07-29 | — | — | US | disclosed |
| US-8754097-B2 | Piperidine and piperazine derivatives | MERCK PATENT GMBH (DE) | 2014-06-17 | — | — | US | disclosed |
| US-20120316162-A1 | PIPERIDINE AND PIPERAZINE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2012-12-13 | — | — | US | disclosed |
| US-20110319378-A1 | PIPERIDINONE DERIVATIVES AS MDM2 INHIBITORS FOR THE TREATMENT OF CANCER | AMGEN INC. (US) | 2011-12-29 | — | — | US | disclosed |
| US-20100222341-A1 | PIPERIDINE AND PIPERAZINE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HARTUNG (DE) | 2010-09-02 | — | — | US | disclosed |
| US-7619094-B2 | Ketoamides with cyclic P4's as inhibitors of NS3 serine protease of hepatitis C virus | SCHERING CORPORATION (US) | 2009-11-17 | — | — | US | disclosed |
| US-20070093430-A1 | Novel ketoamides with cyclic P4's as inhibitors of NS3 serine protease of hepatitis C virus | MERCK SHARP & DOHME CORP. | 2007-04-26 | — | — | US | disclosed |
| US-7173057-B2 | Ketoamides with cyclic P4'S as inhibitors of NS3 protease of hepatitis C virus | SCHERING CORPORATION (US) | 2007-02-06 | — | — | US | disclosed |
| EP-0885941-B1 | Ink jet inks containing oxazolidinones | XEROX CORP (US) | 2004-02-18 | — | — | EP | disclosed |
| US-6225370-B1 | FOR USE WITH INK JET PRINTERS | LEXMARK INTERNATIONAL, INC. | 2001-05-01 | — | — | US | disclosed |
| US-5882389-A | WATER, COLOR AND OXAZOLIDINONE | XEROX CORPORATION (US) | 1999-03-16 | — | — | US | disclosed |
| EP-0885941-A1 | Ink jet inks containing oxazolidinones | Xerox Corporation (US) | 1998-12-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170183308-A1 | LSD1 Inhibitors | KDM1B, KDM1A, KDM3A | PIK3CD 3138/4885CHRNA7 2215/4885GRIN1 675/4885 |
| US-20170355707-A1 | BICYCLIC HETEROARYL AMINE COMPOUNDS | PIK3R3, JAK2, JAK3 | PIK3CD 14/4885CHRNA7 1603/4885GRIN1 730/4885 |
| US-20120316162-A1 | PIPERIDINE AND PIPERAZINE DERIVATIVES | CCND2, CCND1, TPD52L2 | PIK3CD 2693/4885CHRNA7 3494/4885GRIN1 279/4885 |
| US-20110319378-A1 | PIPERIDINONE DERIVATIVES AS MDM2 INHIBITORS FOR THE TREATMENT OF CANCER | MDM2, TP53, CDKN1A | PIK3CD 493/4885CHRNA7 4767/4885GRIN1 2880/4885 |
| US-20070093430-A1 | Novel ketoamides with cyclic P4's as inhibitors of NS3 serine protease of hepatitis C virus | PREP, PRSS1, P4HB | PIK3CD 850/4885CHRNA7 4873/4885GRIN1 4710/4885 |
| US-20100222341-A1 | PIPERIDINE AND PIPERAZINE DERIVATIVES | CCND2, CCND1, TPD52L2 | PIK3CD 2693/4885CHRNA7 3494/4885GRIN1 279/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.